Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

<p><strong>Objectives</strong> To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.</p> <p><strong>Methods</strong> Patients co...

Full description

Bibliographic Details
Main Authors: Coates, LC, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gosse, L, Orbai, A-M, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Merola, JF
Format: Journal article
Language:English
Published: BMJ Publishing Group 2024

Similar Items